Staphylococcus aureus bacteremia in patients receiving pegylated interferon-alpha and ribavirin for chronic hepatitis C virus infection

Journal of Viral Hepatitis

Volumn 14, Issue 8, 2007, Pages 564-569

  Webster, D ^b   Ahmed, R ^b   Tandon, P ^b   Chui, L ^b   McDonald, R R ^c   Obarianyk, A ^c   Antonishyn, N ^c   Doucette, K ^a,b  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Provincial Laboratory   (Canada)

Author keywords

Adverse effects; Antiviral agents; Bacteremia; Hepatitis C; Staphylococcus aureus

Indexed keywords

CLOXACILLIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADULT; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ARTICLE; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL STRAIN; BACTERIUM ISOLATE; CASE REPORT; DISEASE DURATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOCARDITIS; EPIDEMIOLOGICAL DATA; EPIDURAL ABSCESS; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ABUSE; LIVER CIRRHOSIS; MALE; MOLECULAR TYPING; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RISK FACTOR; SEPSIS; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION;

ADULT; ALBERTA; ANTIVIRAL AGENTS; DNA, BACTERIAL; DRUG THERAPY, COMBINATION; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RIBAVIRIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 34447571632     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00828.x     Document Type: Article

References (16)

1. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
2. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
4. Puoti M, Babudieri S, Rezza G et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation Antiviral Ther 2004 9 : 627 630.
5. Ahmed F, Jacobson IM, Brown RS, Brass C. Clinical significance of pegylated interferon induced neutropenia: results of the Win R trial. Gastroenterology 2003 124 : abstract 213.
6. Gaglio PJ, Choi L, Zimmerman D, Heller L, Brown RS. Pegylated interferon (alpha-2B) and ribavirin (Rebetrol) for the treatment of HCV infected patients who failed prior therapy: sustained response data. Gastroenterology 2004 126 : abstract M1230.
7. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994 20 : 15 20.
8. Mulvey MR, Chui L, Ismail J et al. Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis. J Clin Microbiol 2001 39 : 3481 3485.
9. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995 33 : 2233 2239.
10. Antonishyn NA, McDonald RR, Chan EL et al. Evaluation of fluorescence-based amplified fragment length polymorphism analysis for molecular typing in hospital epidemiology: comparison with pulsed-field gel electrophoresis for typing strains of vancomycin-resistant Enterococcus faecium. J Clin Microbiol 2000 38 : 4058 4065.
11. Petti CA, Fowler VG Jr., Staphylococcus aureus bacteremia and endocarditis. Infect Dis Clin North Am 2002 16 : 413 435, x xi.
12. Navasa M, Rodes J. Bacterial infections in cirrhosis. Liver Int 2004 24 : 277 280.
13. Chapoutot C, Pageaux GP, Perrigault PF et al. Staphylococcus aureus nasal carriage in 104 cirrhotic and control patients. A prospective study. J Hepatol 1999 30 : 249 253.
14. Grady R, Blanc D, Hauser P, Stanley J. Genotyping of European isolates of methicillin-resistant Staphylococcus aureus by fluorescent amplified-fragment length polymorphism analysis (FAFLP) and pulsed-field gel electrophoresis (PFGE) typing. J Med Microbiol 2001 50 : 588 593.
15. Ip M, Lyon DJ, Chio F, Enright MC, Cheng AF. Characterization of isolates of methicillin-resistant Staphylococcus aureus from Hong Kong by phage typing, pulsed-field gel electrophoresis, and fluorescent amplified-fragment length polymorphism analysis. J Clin Microbiol 2003 41 : 4980 4985.
16. Hookey JV, Edwards V, Patel S, Richardson JF, Cookson BD. Use of fluorescent amplified fragment length polymorphism (fAELP) to characterise methicillin-resistant Staphylococcus aureus. J Microbiol Methods 1999 37 : 7 15